Portal Capital Riesgo’s Post

Ever wondered how advanced technologies are reshaping cancer care? 💡 Vinaver Medical, one of the top 12 startups in our Labena Ventures accelerator programme, is doing just that. Their mission? To make particle therapy, an incredibly precise cancer treatment—more accessible and effective for millions of patients worldwide. 🌍 In our latest blog, we dive into their inspiring story: how a team of young physicists, IT experts, and a leading radiologist turned their vision into a breakthrough solution. Discover how they’re improving the accuracy of cancer treatments, securing prestigious partnerships with Duke University and Erasmus Hospital, and standing out in an industry dominated by giants like Siemens and GE. This isn’t just about technology—it’s about saving lives. 🙌 Check out the full story and see how innovation is pushing the boundaries of healthcare. ✨ 🔗 Read more and learn how Vinaver Medical is changing the game 👉 https://lnkd.in/dErngT5h . #HealthTech #StartupStory #Innovation #CancerTreatment #ParticleTherapy #VinaverMedical #LabenaVentures #Startups

Sycai Medical, a Barcelona-based HealthTech startup, today announced the successful closure of their €3 million investment round to develop and commercialise their AI cancer detecting digital device 🇪🇸 🩺 The round included participation from the pan-European consortium of LUMO Labs, Ship2B Ventures, Athos Capital and Namarel Ventures for the further development and roll-out of their AI-driven digital medical device that detects early cancer and pre-malignant lesions in the abdomen from medical imaging without any invasive test. Sara Toledano, Sycai CEO & Co-founder, “Successfully completing this investment round marks a significant milestone for us at a very strategic moment in the company’s evolution. We are currently undergoing a transformation from a product-driven to a business-driven organization, due to the MDR approval and initiation of commercial activities. We are confident that our new investors will play a pivotal role in fostering a refreshed mindset to support this transition.” https://lnkd.in/d9GWr9kd

HealthTech Sycai Medical raises €3 million to improve early diagnosis of cancer in the abdomen: Sycai Medical, a Barcelona-based HealthTech startup, today announced the successful closure of their €3 million investment round to develop and commercialise their AI cancer detecting digital device. The round included participation from the pan-European consortium of LUMO Labs, Ship2B Ventures, Athos Capital and Namarel Ventures for the further development and roll-out of their AI-driven digital.. #Funding #SpainStartups

🌍💡 Spotlight on Europe’s Emerging CancerTech Startups 💡🌍 🎗 The fight against cancer is evolving, and Europe is at the forefront with a wave of #innovative startups making significant strides in cancer #technology. From early detection to personalized treatment, these companies are harnessing cutting-edge tech to transform patient outcomes. 🌟 As we witness these exciting #developments, it's clear that #collaboration and innovation will be key to overcoming one of humanity's greatest challenges. Here are some emerging cancer tech startups in Europe, including: Kuano, Antiverse, Awell, Careology, CliniNote, DeepLife, Concr, Orakl Oncology, Panakeia, PreComb, Sonrai, Ignota Labs, Neuroute, Sycai Medical, Alvie Health, RECEPTOR.AI, Tailor. bio, TrialHub, DiaDeep, Onocochain To share your startup story write us on - [email protected] #Cancerstartup #Europeanstartup #startup

OneCell Diagnostics Inc. Diagnostics has raised $16 million in a Series A funding round led by Celesta Capital, alongside Tenacity Ventures, Cedars-Sinai, Eragon and Singularity Ventures. The funding will drive the US expansion of its cutting-edge liquid biopsy test, OncoIndx Alfa, designed to detect circulating tumor cells for precision cancer diagnosis. Founded in 2021, the startup utilizes next-generation sequencing, AI/ML, and data analytics to create advanced biomarkers. Collaborating with AIIMS, Tata Memorial Centre, and institutions like Harvard and Stanford, OneCell has already tested its biopsy technology on 10,000 patients in India, making strides in cancer care innovation. #OneCellDiagnostics #CancerInnovation #SeriesAFunding #OncoIndxAlfa #BiotechStartup #PrecisionDiagnostics #HealthcareTech #AIinMedicine #CancerCare #Startup77

Manas AI, a startup co-founded by LinkedIn’s Reid Hoffman and renowned cancer researcher Siddhartha Mukherjee, has raised $24.6 million in seed funding to leverage AI in drug discovery. The company will initially focus on developing treatments for breast cancer, prostate cancer, and lymphoma. The funding comes from Hoffman, General Catalyst, and Greylock, though it’s significantly smaller compared to other AI-driven drug discovery startups. For instance, Xaira raised $1 billion, and Treeline Biosciences secured $422 million last year. Manas AI plans to design AI-driven molecules and test them in wet labs, using Microsoft Azure’s cloud platform to advance its research. Hoffman, with strong ties to Microsoft through LinkedIn’s acquisition, will also benefit from the tech giant's expertise. #digitalorators #do #ai #artificialintelligence #linkedin #reidhoffman #azurecloud #microsoft #drugdiscovery #biotech #healthcare #healthtech

Titre : Reid Hoffman’s Manas AI raises $24.6M, a fraction of other AI drug discovery startups Description : Reid Hoffman and Siddhartha Mukherjee have launched an AI-driven drug discovery startup, Manas AI, focusing on breast cancer, prostate cancer, and lymphoma, securing $24.6 million in seed funding. Link :

UK medtech startup 52North bags €5.7M to accelerate oncology-focused innovations: On Wednesday, Cambridge, UK-based 52North, the medtech company focused on transforming urgent care pathways in oncology, announced that it has secured $6M (approximately €5.7M) in a funding round. The funding round was co-led by KHP Ventures, affiliated with King’s Health Partners in London, and Cedars-Sinai Intellectual Property Co. in California, affiliated with Cedars-Sinai Medical Center. ... Read more #UKMedtech #52North #Oncology

#startupnews #fundingalert Karna D Shinde Invests in Navaux for Cancer Detection Innovation Karna D. Shinde, a strategic investor known for his investments in health tech and innovative startups, has invested in Navaux, a company at the forefront of cancer detection technology. Navaux has developed a breakthrough blood test that detects early-stage cancer by identifying the protein Hepsin, which is produced by tumor cells. This innovative approach aims to provide a simple and effective method for early cancer detection, potentially revolutionizing the healthcare industry. Navaux's technology promises to make early cancer detection more accessible and less invasive, significantly improving patient outcomes. The investment from Karna D. Shinde will enable Navaux to further develop its technology, expand its market reach, and enhance its research and development efforts. Shinde's strategic insight and financial support are expected to play a crucial role in accelerating Navaux's growth and success in the healthcare sector. #HealthTech #CancerDetection #Innovation #EarlyDetection #HealthcareRevolution #KarnaShinde #Navaux #Investment #TechForGood #HealthcareInnovation #MedicalBreakthrough #Biotech #CancerResearch #StartupSuccess #PatientCare #LifeSciences #FutureOfHealthcare #EarlyIntervention #MedicalTechnology #Oncology

Alphan Manas Manas AI 🤖 sana çok yakışır 😉 Reid Hoffman’s Manas AI raises $24.6M, a fraction of other AI drug discovery startups LinkedIn founder Reid Hoffman and Siddhartha Mukherjee researcher and author of the book “The Emperor of All Maladies,” have co-founded an AI-powered drug discovery startup, Manas AI. The company, which will initially focus on breast cancer, prostate cancer, and lymphoma, has raised $24.6 million in seed funding from Hoffman, General Catalyst, and Greylock.